✦ LIBER ✦

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects

✍ Scribed by Pettitt, A R; Matutes, E; Oscier, D

Book ID: 110056783
Publisher: Nature Publishing Group
Year: 2006
Tongue: English
Weight: 96 KB
Volume: 20
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2404265

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab in Combination With Methylpr

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

✍ Pettitt, A. R.; Jackson, R.; Carruthers, S.; Dodd, J.; Dodd, S.; Oates, M.; John 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 246 KB